Evidence-Based. Clearly Delivered.
Evidence-Based. Clearly Delivered.
Electromechanical morcellation has been instrumental in advancing the field of minimally invasive gynecologic surgery. Recently, the technique has come under scrutiny due to the concern of inadvertent morcellation and dissemination of malignant cells in the setting of uterine cancer (for example leiomyosarcoma). Currently, there is limited data as to whether there is a difference in safety between vaginal and peritoneal morcellation. This study by Wasson et al. (Journal of Minimally Invasive Gynecology, 2017) sought to determine the incidence of occult uterine malignancy at the time of vaginal hysterectomy and secondarily, peri-operative data as well as long-term patient outcomes.
Retrospective Cohort Study
2,296 women across three institutions underwent total vaginal hysterectomy. 73.39% of women did not have vaginal morcellation and 611 women did undergo vaginal morcellation via cold-knife wedge resection. All patients requiring morcellation had benign indications for hysterectomy and all surgeries were performed by gynecologists with subspecialty training in minimally invasive surgery. In the non-morcellation group, occult malignancy was found in 5 patients (0.3%) of patients; Stage IA, grade I endometrial adenocarcinoma in 4 patients (0.24%), and low-grade stromal sarcoma was found in 1 patient (0.06%). In the morcellation group, 5 patients (0.82%) had an occult uterine malignancy; stage IA, grade I endometrial adenocarcinoma in 3 patients (0.49%) and low grade stromal sarcoma in 2 patients (0.33%). There were no cases of uterine sarcoma. In all 5 patients, the initial indication for hysterectomy was abnormal uterine bleeding and all patients underwent uterine sampling and pelvic imaging. All the patients have remained disease-free and no deaths have occurred with a mean disease-free survival of 48.33 months (range, 33-67 months) for those with endometrial adenocarcinoma and 42.0 months (range, 19-65 months) for patients with stromal carcinoma. The authors recognize limitations of the study, including retrospective design, limited sample size and subspecialty surgeons. The authors conclude that for patients undergoing uncontained vaginal hysterectomy with morcellation, prognosis in the setting of occult endometrial carcinoma or low-grade stromal sarcoma was not adversely affected.
Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation
The contents of this Site, such as text, graphics, images, information obtained from The ObG Project’s licensors, and other material contained on the Site (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional legal or medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on the Site!
If you think you may have a medical emergency, call your doctor or 911 immediately. The ObG Project does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site. Reliance on any information provided by The ObG Project, The ObG Project employees, others appearing on the Site at the invitation of The ObG Project, or other visitors to the Site is solely at your own risk.
The Site may contain health- or medical-related materials that are sexually explicit. If you find these materials offensive, you may not want to use our Site.
Children’s Privacy
We are committed to protecting the privacy of children. You should be aware that this Site is not intended or designed to attract children under the age of 13. We do not collect personally identifiable information from any child we reasonably believe is under the age of 13.
Continue with ObGFirst™
Read the full article, unlock patient-friendly tools, and access subscriber resources across the site.
Get ObGFirst™ for only $9/mo
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
